Please assess the completion status of the following clinical trial:

Trial Title: BI 671800 ED in Steroid-naive Asthmatic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~1. Signed informed consent consistent with ICH-GCP~2. Three month history of reversible (12% with 200 mL) asthma (according to GINA) with following spirometry at randomization: FEV1 60%-85%.~3. No ICS previous 3 months prior to screening.~4. Diagnosis of asthma prior to 40 years.~5. ACQ at least 1.5 at randomization.~6. Male or female, 18 to 65 years.~7. Non-smokers or ex-smokers ( less than 10 pack year history) with negative cotinine screen.~8. Able to perform PFT~Exclusion criteria:~1. Significant diseases other than asthma or allergic rhinitis.~2. Hepatic transaminases or total bilirubin greater than 1.5 ULN.~3. Hospitalizations for asthma or asthma related intubation within 3 months.~4. Uncontrolled asthma.~5. Respiratory tract infection or exacerbation within 4 weeks.~6. FEV1 less than 40%, more than 12 puffs of SABA on more than two consecutive days or asthma exacerbation during the run-in period.~7. Participation in another interventional study.~8. Pregnant or nursing women.~9. Women of child bearing potential nor using appropriate methods of birth control as defined by protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- BI 671800 (low dose) (Type: EXPERIMENTAL): Patients receive BI 671800 (low dose) capsules twice daily
- Fluticasone propionate (Type: ACTIVE_COMPARATOR): Patients inhale from Fluticasone propionate metered dose inhaler (MDI) twice daily
- Placebo (Type: PLACEBO_COMPARATOR): Patients receive placebo capsules twice daily
- BI 671800 (medium dose) (Type: EXPERIMENTAL): Patients receive BI 671800 (medium dose) capsules twice daily
- BI 671800 (high dose) (Type: EXPERIMENTAL): Patients receive BI 671800 (high dose) capsules twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).